| 1. |
Cives M, Simone V, Rizzo FM, et al. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol, 2015, 95(1): 1-11.
|
| 2. |
楊光杰, 聶佩, 王振光. Erdheim-Chester病的影像學研究進展. 中華醫學雜志, 2016, 96(37): 3036-3038.
|
| 3. |
王珊, 任翠萍, 李瑩, 等. 骨骼脂性肉芽腫影像學特征分析. 中華醫學雜志, 2016, 96(31): 2478-2481.
|
| 4. |
Munoz J, Janku F, Cohen PR, et al. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc, 2014, 89(7): 985-996.
|
| 5. |
Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis, 2013, 72(10): 1691-1695.
|
| 6. |
張利娟, 林全德, 董麗華, 等. 非朗格罕斯細胞組織細胞增多癥一例報告并文獻復習. 中華血液學雜志, 2013, 34(7): 634-636.
|
| 7. |
Blombery P, Wong SQ, Lade S, et al. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol, 2012, 30(32): e331-e332.
|
| 8. |
Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol, 2015, 5(33): 418-421.
|
| 9. |
Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with inflixima. J Clin Oncol, 2012, 28(30): e286-e290.
|
| 10. |
Bulycheva EN, Baykov VV, Zara?ski? MI, et al. Rare form of erdheim-chester disease presenting with isolated central skeletal lesions treated with a combination of alfa-interferon and zoledronic acid. Case Rep Hematol, 2015, 2015: 876752.
|
| 11. |
Franco P, Filippi AR, Ciammella P, et al. Polyostotic sclerosing histiocytosis (Erdheim-Chester disease) treated with combined vertebroplasty and radiation therapy. Tumori, 2010, 96(4): 633-636.
|
| 12. |
Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are in dependent prognostic factors in Erdheim-Chester disease:a multicenter survival analysis of 53 patients. Blood, 2011, 117(10): 2778-2782.
|
| 13. |
Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single center series of 37 patients. Blood, 2011, 117(10): 2783-2790.
|
| 14. |
Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood, 2010, 116(11): 1919-1923.
|
| 15. |
Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol, 2012, 24(1): 53-59.
|
| 16. |
王晶石, 王昭. 脂質肉芽腫病診斷及治療進展. 中國實驗血液學雜志, 2016, 24(4): 1256-1259.
|
| 17. |
Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood, 2010, 116(20): 4070-4076.
|
| 18. |
曹振, 周云峰. Erdheim-Chester病的診斷和治療. 醫學新知雜志, 2017, 27(1): 16-20.
|
| 19. |
Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med, 2001, 135(9): 844-845.
|
| 20. |
Cao XX, Sun J, Li J, et al. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol, 2016, 95(5): 745-750.
|
| 21. |
Rademacher S, Anagnostopoulos J, Luft FC, et al. Erdheim-Chester disease and knee pain in a dialysis patient. Clin Kidney J, 2014, 7(4): 402-405.
|
| 22. |
Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore), 1996, 75(3): 157-169.
|
| 23. |
胡金波, 龔莉琳, 汪志紅, 等. 以尿崩癥起病的Erdheim-Chester病一例報道. 中華內分泌代謝雜志, 2013, 29(6): 536-537.
|
| 24. |
Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol, 2012, 24(1): 53-59.
|
| 25. |
Saboerali MD, Koolen MG, Noorduyn LA, et al. Pleural thickening in a construction worker: it is not always mesothelioma. Neth J Med, 2006, 64(3): 88-90.
|
| 26. |
Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 2017, 130(2): 167-175.
|